title: Toward molecular imaging-driven drug development in oncology.
abstract: With current testing strategies, the number of novel targeted anticancer agents will exceed our drug selection capacity. Molecular imaging is a powerful additional tool that can assist us in selecting effective drugs and help patients benefit from targeted agents. Moreover, measurement of the functional effects of such targeted agents could permit dynamic tuning of treatment selection at the earliest time point at which loss of functional effects is observed.
authors.affiliation: Department of Medical Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. e.g.e.de.vries@int.umcg.nl
authors.forename: Elisabeth G E
authors.initials: EG
authors.lastname: de Vries
authors.forename: Thijs H
authors.initials: TH
authors.lastname: Oude Munnink
authors.forename: Marcel A T M
authors.initials: MA
authors.lastname: van Vugt
authors.forename: Wouter B
authors.initials: WB
authors.lastname: Nagengast
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000191:economics / Q000379:methods*; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D057054:Molecular Imaging / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000191:economics / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics; D057285:Precision Medicine / Q000191:economics